Jose Cuervo, the world’s top-selling tequila brand, says it is not a supporter of the additive-free campaign that has swept ...
In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...
Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B ...
Pharmaceutical Technology on MSN12d
Curevo procures $110m and former-GSK exec for shingles vaccine candidateCurevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...
Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...
Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former executive from the UK big pharma to advance its candidate amezosvatein.
Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...
Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic ...
Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback